{"id":"NCT00536913","sponsor":"AstraZeneca","briefTitle":"Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma","officialTitle":"A 4-week, Open-label, Randomized, Multi-centre, Parallel-group Study Evaluating the Safety and Efficacy of 4 Actuations Symbicort® (Budesonide/Formoterol) HFA pMDI 40/2.25 μg Twice Daily, With and Without Spacer, in Children (6-11 Years) With Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2008-02","completion":"2008-02","firstPosted":"2007-09-28","resultsPosted":"2012-02-27","lastUpdate":"2012-04-06"},"enrollment":107,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Budesonide/formoterol pMDI 40/2.25ug + spacer","otherNames":[]},{"type":"DRUG","name":"Budesonide/formoterol pMDI 40/2.25 ug","otherNames":[]}],"arms":[{"label":"With Spacer","type":"EXPERIMENTAL"},{"label":"Without Spacer","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to compare Symbicort pMDI with and without spacer in terms of steroid potency, improvement of lung function and asthma symptoms in children with asthma (6-11 years).","primaryOutcome":{"measure":"Urinary Free Cortisol (UFC)","timeFrame":"At baseline and 4 weeks","effectByArm":[{"arm":"With Spacer","deltaMin":0.86,"sd":null},{"arm":"Without Spacer","deltaMin":1.03,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":11,"countries":["Hungary","Poland","Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":55},"commonTop":[]}}